Skip to the main content.

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

MELBOURNE Australia, 5 June 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development, is pleased to announce that it has secured agreements critical to the development of its lead therapeutic program, AD-214. Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing services.

Read Full Press Release from AdAlta (PDF)

 

 

 

 

 

 

 

KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing

KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing

Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes ...

Read More
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners

JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners

KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers Sunnyvale,...

Read More
KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer

KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer

Durham, North Carolina (May 10, 2023)  – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay...

Read More